Posts Tagged Bio/Pharma

Growing Mexico Is Home to Solid CMO Population

by

Proximity to the US, a strong regulatory scheme, affordability and decades-long relationships forged with the help of the North American Free Trade Agreement (NAFTA) are among the factors that may make Mexico an attractive location for contract manufacturing services, particularly for products sold in the US or Latin American markets. The country is also fairly […]

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on AmpliPhi Biosciences Corporation

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. AmpliPhi Biosciences, (formerly known as Targeted Genetics Corporation), develops gene-based products for the treatment of acquired and inherited diseases. It raised $9.1 million in a […]

Learn more

Big Pharma Capex Continues to Grow, but Rate Slows

by

Spending by global bio/pharmaceutical companies on new plant and equipment grew by an average of 2.7% in 2016, compared to sales growth of 4.4% (see Figure 1, below). This is the first year in recent times that revenue growth has outpaced capex growth. Moreover, the increase in capital expenditure represented a significant decline from the […]

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on ContraVir Pharmaceuticals, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. ContraVir Pharmaceuticals is a U.S. public bio/pharmaceutical company that develops and commercializes targeted antiviral therapies for the treatment of Hepatitis B, shingles and shingles pain. […]

Learn more

CMOs and CROs Have Different Trajectories

by

CMOs may be gaining as strategic partners to large bio/pharma companies, but they have a much harder path to navigate. A growing number of observers, including the Wall Street analysts that follow the publicly-traded contract research organizations (CROs) and contract manufacturing organizations (CMOs), have made statements recently suggesting that the CMO industry is following the […]

Learn more

Strong Economic Growth Draws Pharma Companies to Malaysia

by

A rapidly growing pharma market and environment friendly to clinical trials are among the features that are attracting a growing number of multinational pharmaceutical companies to Malaysia. However, those pluses are balanced by decided favoritism toward domestic production, seen in government supply contracts and tax codes. According to a September 2016 report by PharmSource’s colleagues […]

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on BioCryst Pharmaceuticals, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. BioCryst Pharmaceuticals is a U.S. public bio/pharmaceutical company that discovers drugs for the treatment of infectious diseases, inflammatory diseases and cancer. It plans to raise […]

Learn more

Bio/Pharmaceutical Outsourcing Report – Special DCAT 2017 Edition

by

PharmSource has published a special DCAT Edition of our proprietary industry briefing, Bio/Pharmaceutical Outsourcing Report. This monthly report reports on and analyzes major developments throughout the CMO industry. It provides expert insight into the significance of industry trends and what they mean for your business. Deepen your understanding of what’s happening in commercial and clinical […]

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Aldeyra Therapeutics, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Aldeyra Therapeutics is a U.S. public bio/pharmaceutical company that develops potent, small molecule, irreversible aldehyde traps for the treatment of diseases caused by inflammation and […]

Learn more